The Crypto Secret Wall Street Doesn’t Want You to Know

The Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech giants are quietly integrating it. Venture capitalists are scrambling to invest.

Click here to discover our #1 crypto for the market right now – poised for massive growth

Brian Elsbernd Biography and Net Worth

Chief Legal and Compliance Officer of Catalyst Pharmaceuticals

Brian Elsbernd joined Catalyst in February 2016 as the Senior Vice President of Legal and Compliance and was promoted to Chief Legal and Compliance Officer in December 2018. Prior to joining Catalyst, Mr. Elsbernd was Senior Director of US Healthcare Compliance at Mallinckrodt Pharmaceuticals, a growing US specialty pharmaceutical business. From its inception, he led their healthcare compliance and business ethics program while also managing multiple other legal and business functions. Previously, Mr. Elsbernd was an associate at Proskauer Rose LLP, within its Health Care practice group, representing healthcare providers nationwide in matters pertaining to regulatory and administrative law, transactional matters, litigation, and reimbursement issues. Mr. Elsbernd earned his law degree from Saint Louis University School of Law and his undergraduate degree at the University of Illinois.

What is Brian Elsbernd's net worth?: The estimated net worth of Brian Elsbernd is at least $2.69 million as of March 27th, 2024. Mr. Elsbernd owns 124,433 shares of Catalyst Pharmaceuticals stock worth more than $2,693,974 as of December 17th. This net worth approximation does not reflect any other investments that Mr. Elsbernd may own. Additionally, Mr. Elsbernd receives an annual salary of $311,420.00 as Chief Legal and Compliance Officer at Catalyst Pharmaceuticals. Learn More about Brian Elsbernd's net worth.
How old is Brian Elsbernd?: Mr. Elsbernd is currently 60 years old. There are 6 older executives and no younger executives at Catalyst Pharmaceuticals. The oldest executive at Catalyst Pharmaceuticals is Dr. Gary Ingenito M.D., Ph.D., Chief Medical & Regulatory Officer, who is 68 years old. Learn More on Brian Elsbernd's age.
What is Brian Elsbernd's salary?: As the Chief Legal and Compliance Officer of Catalyst Pharmaceuticals, Inc., Mr. Elsbernd earns $311,420.00 per year. There are 4 executives that earn more than Mr. Elsbernd. The highest earning executive at Catalyst Pharmaceuticals is Dr. Steven R. Miller Ph.D., Executive VP, COO & Chief Scientific Officer, who commands a salary of $884,700.00 per year. Learn More on Brian Elsbernd's salary.
How do I contact Brian Elsbernd?: The corporate mailing address for Mr. Elsbernd and other Catalyst Pharmaceuticals executives is 355 ALHAMBRA CIRCLE SUITE 1250, CORAL GABLES FL, 33134. Catalyst Pharmaceuticals can also be reached via phone at (305) 420-3200 and via email at [email protected]. Learn More on Brian Elsbernd's contact information.
Has Brian Elsbernd been buying or selling shares of Catalyst Pharmaceuticals?: Brian Elsbernd has not been actively trading shares of Catalyst Pharmaceuticals within the last three months. Most recently, Brian Elsbernd sold 25,000 shares of the business's stock in a transaction on Wednesday, March 27th. The shares were sold at an average price of $16.44, for a transaction totalling $411,000.00. Following the completion of the sale, the insider now directly owns 124,433 shares of the company's stock, valued at $2,045,678.52. Learn More on Brian Elsbernd's trading history.
Who are Catalyst Pharmaceuticals' active insiders?: Catalyst Pharmaceuticals' insider roster includes Philip Coelho (Director), Richard Daly (President and CEO), Jeffrey Del Carmen (EVP, Chief Commercial Officer), Donald Denkhaus (Director), Brian Elsbernd (Chief Legal and Compliance Officer), Alicia Grande (Vice President, Chief Financial Officer and Treasurer), Alicia Grande (CFO), Molly Harper (Director), Gary Ingenito (Insider), Patrick McEnany (CEO), Steve Miller (COO), Steven Miller (COO & Chief Scientific Officer ), and David Tierney (Director). Learn More on Catalyst Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Catalyst Pharmaceuticals?: In the last year, insiders at the biopharmaceutical company sold shares 12 times. They sold a total of 440,755 shares worth more than $8,352,888.44. The most recent insider tranaction occured on December, 10th when insider Steve Miller sold 50,000 shares worth more than $1,096,500.00. Insiders at Catalyst Pharmaceuticals own 11.0% of the company. Learn More about insider trades at Catalyst Pharmaceuticals.
Information on this page was last updated on 12/10/2024.

Brian Elsbernd Insider Trading History at Catalyst Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/27/2024	Sell	25,000	$16.44	$411,000.00	124,433
3/20/2023	Sell	50,000	$16.07	$803,500.00	138,076

Brian Elsbernd Buying and Selling Activity at Catalyst Pharmaceuticals

Catalyst Pharmaceuticals Company Overview

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.

Today's Range

Now: $21.65

$21.33

$22.03

50 Day Range

MA: $21.65

$19.91

$23.93

2 Week Range

Now: $21.65

$13.12

$24.27

Volume

722,412 shs

Average Volume

1,167,456 shs

Market Capitalization

$2.58 billion

P/E Ratio

18.35

Dividend Yield

N/A

Beta

0.75

The Crypto Secret Wall Street Doesn’t Want You to Know

From Crypto 101 Media | Ad

The Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech giants are quietly integrating it. Venture capitalists are scrambling to invest.

Click here to discover our #1 crypto for the market right now – poised for massive growth

Brian Elsbernd Biography and Net Worth

What is Brian Elsbernd's net worth?

How old is Brian Elsbernd?

What is Brian Elsbernd's salary?

How do I contact Brian Elsbernd?

Has Brian Elsbernd been buying or selling shares of Catalyst Pharmaceuticals?

Who are Catalyst Pharmaceuticals' active insiders?

Are insiders buying or selling shares of Catalyst Pharmaceuticals?